Treating Migraine with Nerve Stimulation Devices

Nerve Stimulation Devices for Migraine Treatment

Nerve Stimulation Devices for Migraine Treatment
Cefaly.com

If you experience migraine, whether chronic or episodic, there may be a “zap” for that.

Bad wordplay aside, nerve stimulation has proved to be an effective option for some people who have this often painful neurological disease.

“The underlying theory is there are targets in the central and peripheral nervous systems that can be manipulated using electrical or magnetic pulses on nerves that are directly or indirectly involved in pain processing,” explains Matthew Robbins, MD, an associate professor of neurology at NewYork-Presbyterian and Weill Cornell Medicine in New York City.

“In most people, I don’t see nerve stimulation replacing medication altogether, but it can be used alongside prescribed drug treatment to reduce migraine episodes or pain intensity,” says Dr. Robbins. “It may also help reduce reliance on medication to address symptoms,” he adds.

Types of Nerve Stimulation Devices

Nerve stimulation, sometimes called neuromodulation, isn’t one single approach.

Although they generally work the same way, the methods vary according to which nerves are targeted in the procedure and how the stimulation is applied. These are the most commonly used approaches for migraine:

  • Supraorbital stimulation targets the branch of the trigeminal nerve that brings sensation to the forehead, upper eyelid, and scalp.
  • Vagus nerve stimulation (VNS) targets the vagus nerve, which extends from the brainstem to the abdomen and communicates with a variety of muscles and organs along its entire length, including the small intestine and colon.
  • Occipital nerve stimulation (ONS) targets nerves on the back of the scalp.
  • Remote electrical neuromodulation (REN) stimulates peripheral nerves in the arm, with the goal of blocking pain signals from reaching the brain.
  • Single-pulse transcranial magnetic stimulation (sTMS) is not aimed at any particular nerve but rather at the brain more generally.
Nerve-Stimulation-Devices-for-Migraine-Treatment-Nerivio-3-1440x810
The Nerivio device is approved for both the prevention and treatment of migraine.Photo courtesy of Theranica

Trigeminal Nerve Stimulation

In supraorbital stimulation, or external trigeminal nerve stimulation (e-TNS) — sometimes referred to as transcutaneous electrical nerve stimulation (TENS) — your doctor recommends a specific level of microimpulses that target the upper branch of the trigeminal, or supraorbital, nerves, which research suggests are involved in migraine attacks.

These pulses are delivered using a device that you place on your head when you feel a migraine attack coming on, or during an attack to relieve pain. The device is available with a prescription or over-the-counter (no prescription required) in many pharmacies.

Once your doctor has suggested an appropriate level of stimulation for your migraine symptoms, you administer the treatment yourself at home.

Research has found that using an e-TNS device can reduce both the number of migraine attacks you have and the number of headache days you have per month, and reduce the amount of prescription medicine you need to treat symptoms.

Cefaly

The Cefaly external e-TNS device is designed to be worn on the forehead. It uses magnets to attach to a reusable electrode that sticks to the skin with adhesive. The device can be used once daily for 20 minutes to prevent attacks and for up to 60 minutes during a migraine attack to relieve symptoms. The user chooses a preventive or acute program when applying the device and selects the intensity of the treatment. The device turns off automatically when the program is complete.

The U.S. Food and Drug Administration (FDA) first approved the Cefaly device for the prevention of migraine attacks in 2014 on the basis of promising research data. The agency then approved the device for use in the treatment of migraine attacks in 2017.

In 2020, the FDA cleared the Cefaly Dual as an over-the-counter product to prevent and treat migraine in adults ages 18 and older.

Newer models have features like softer indicator lights and Bluetooth connectivity. They retail for about $400. Electrodes, good for multiple uses, cost about $8 each.

Relivion

Another e-TNS device, Relivion is a noninvasive headset that delivers pulses of electrical current to stimulate the occipital and trigeminal nerves.

The headset has two sensors that sit on either side of the nose (similar to the nosepieces of eyeglasses) and is intended to be put on and activated at the onset of a migraine attack. The amount and type of modulation can be controlled via an app on a paired smartphone.

The device received FDA clearance in the United States in March 2021 for at-home treatment of acute migraine in adults. It requires a doctor’s prescription.

In the clinical trial on which the FDA based its approval, 46 percent of users reported pain freedom at two hours, and 75 percent reported freedom from their most bothersome symptom — nausea, light sensitivity, or sound sensitivity — at two hours.

Vagus Nerve Stimulation

VNS is another self-administered approach in which a person with migraine uses a handheld device that delivers small amounts of electrical stimulation to the vagus nerve, which travels from the base of the skull to the abdomen. Users place the device over the nerve at the side of the neck.

In one study, VNS provided pain relief within two hours of the start of a migraine attack, while approximately 30 percent of users were completely pain-free by that time.

GammaCore Sapphire

GammaCore Sapphire is an FDA-cleared (in 2015) handheld device that allows users to self-administer small doses of noninvasive VNS therapy to treat cluster headaches and migraine. The rechargeable and reloadable device is designed for multiyear use.

The device can be used for both acute and preventive migraine and cluster headache treatment. Users apply conductive gel to the two stimulation surfaces, then hold the device against the side of their neck, just below the jawline (either side of the neck will work), so that it can deliver small electrical pulses to the vagus nerve for two minutes at a time. The user controls the intensity of the pulses.

The suggested timing of the two-minute treatments depends on whether the user is preventing or treating migraine, or preventing or treating cluster headache.

Originally, GammaCore was approved for use in adults only. In February 2021, the FDA expanded clearance of the device to include the acute and preventive treatment of migraine in adolescents between ages 12 and 17.

GammaCore Sapphire requires a doctor’s prescription. Before use, the device must be activated with an authorization code, delivered via a radio-frequency identification card.

Without insurance, the GammaCore starter kit, preloaded with three months of therapy, costs $450. However, some healthcare insurance plans cover the device and will reimburse at least some of the charges, according to a story on Everyday Health network site Migraine Again.

Occipital Nerve Stimulation

Implantable occipital nerve stimulation (ONS) involves the surgical implantation of a device that sends electrical pulses to the occipital nerve, which is located at the back of the head, just above the neck. It’s used primarily in people with chronic headache disorders for whom other treatments have failed.

One survey of people with chronic migraine who had an ONS device implanted found that the approach was effective for nearly half of them.

Notably, ONS is different from other nerve stimulation systems in that it involves surgery, but the procedure is reversible.

One implantable device currently in development, from Salvia Bioelectronics, uses mild electrical impulses to influence nerve activity, or the pattern of electrical impulses transmitted through nerve fibers that control how your body functions. The Dutch company is working on implantable thin bioelectronic foils that conform to the shape of the head to deliver neurostimulation.

Specifically, the company’s implantable neurostimulation system (similar to a pacemaker) will be designed to use bioelectronic foil technology to disrupt the brain processes that cause migraine attacks in people for whom drug therapy has failed. In 2020, the FDA granted Salvia a breakthrough device designation for its implantable technology. The designation enables the company to have more frequent interaction with FDA regulatory experts as it prepares the device for approval.

Peripheral Nerve Stimulation

Remote electrical neuromodulation (REN) may be particularly useful for people with migraine who are worried that using devices that apply electrical stimulation to the head area may worsen the pain associated with attacks. Uniquely, this approach is designed to stimulate the peripheral nerves in the upper arm. It is thought to reduce migraine pain by modulating a deep part of the nervous system involved in pain control. Specifically, REN activates pain control centers in the brainstem (the connection between the brain and the spinal cord), which blocks the pain signaling that occurs in migraine, according to Migraine Again.

An analysis of patient data found that up to 74 percent of people who used REN experienced pain relief within two hours, while up to 36 percent of them were pain-free by that time. Less than 1 percent of the people in the study who used the approach had any related side effects.

Nerivio

Nerivio is an FDA-approved wireless remote neuromodulation armband for the prevention and acute treatment of migraine with or without aura in people age 8 and older. The device is controlled by an app designed to provide personalized treatments.

The app features a migraine diary that allows you to track treatment sessions and migraine attacks. You can share the diary with your doctor to guide your migraine management.

Nerivio is available only with a doctor’s prescription at participating pharmacies and telemedicine providers. The first Nerivio device costs $49 with the Nerivio Express Savings Program, which requires that you have a pharmacy or medical insurance plan and that you give the pharmacy permission to run a benefits verification and receive any required prior authorizations. The cost of refill devices depends on the customer's insurance coverage plan.

Each Nerivio device delivers eighteen 45-minute treatments. After 18 treatments, the battery no longer works, and the device will need to be recycled.

Magnetic Stimulation

A potential preventive and acute treatment for migraine, sTMS can be administered at home by placing the sTMS device against the back of your head and activating it. The device delivers a short magnetic pulse (the length is preset by your doctor) that targets the layers of the scalp, the skull, the meninges (membranes that enclose the brain and spinal cord), the cerebrospinal fluid, and the superficial layers of the cortex, where it modulates the electrical environment of neurons involved in migraine attacks.

In research done on using sTMS as a preventive treatment, the device reduced the number of days that people with migraine experienced symptoms. Users also had a decreased need for rescue medication.

SAVI Dual

The eNeura SAVI Dual is an FDA-approved sTMS device that is battery powered, handheld, and can be used for both the prevention and treatment of migraine attacks in adults and children age 12 and older.

The user places and holds the SAVI Dual firmly against the back of the head to cradle the base of the skull. With the push of a button, the device’s specially shaped electrical coils deliver a magnetic pulse designed to treat and prevent migraine attacks by interrupting abnormal electrical activity in the brain associated with them. The device automatically transmits a person’s treatment history to a cloud-based diary, which can be used to improve migraine management.

You need a doctor’s prescription to use the SAVI Dual. A $395 monthly prescription fee includes unlimited acute treatments and daily preventive treatments, according to Migraine Again.

Pros and Cons

Even with nerve stimulation approaches that can be self-administered, people with migraine should consult their doctors before using them, Robbins emphasizes, even if they don’t require a prescription. Your doctor can help you determine which device is right for your migraine symptoms and whether it is safe for you to use, he says.

Although the side effects of nerve stimulation differ depending on the approach used, most are mild, such as redness or irritation and muscle twitching in the area where the device is applied. A handful of people undergoing nerve stimulation have reported feeling light-headed or having a tingling sensation after treatment.

Keep in mind, also, that there are situations in which nerve stimulation can’t be used. People with epilepsy or implanted electrical devices like cardiac pacemakers probably shouldn’t use the technology, Robbins notes. It may be a good choice for people who are avoiding taking medications because they are pregnant or plan to become pregnant, are older, or are taking many other medications, he says.

The self-administered devices can be expensive and most aren’t covered by health insurance.

Despite these considerations, nerve stimulation has an important advantage over most migraine medications. “Some drugs have been linked with what’s called medication-overuse headaches — headaches associated with repeated use of the medications themselves,” Robbins notes. “There doesn’t seem to be the same issue with nerve stimulation. To be honest, it’s a treatment I’d recommend to more patients.”

The Takeaway

  • Nerve stimulation devices treat migraine by delivering electrical or magnetic pulses to specific nerves or areas of the brain.
  • This technique can be used both to treat migraine symptoms and to prevent this type of headache.
  • These devices may allow you to cut back on migraine medication.
  • Most nerve stimulation devices require a prescription, and insurance plans often don’t pay for them.
Jessica-Baity-bio

Jessica Baity, MD

Medical Reviewer

Jessica Baity, MD, is a board-certified neurologist practicing in southern Louisiana. She cares for a variety of patients in all fields of neurology, including epilepsy, headache, dementia, movement disorders, multiple sclerosis, and stroke.

She received a bachelor's degree in international studies and history from the University of Miami and a master's in international relations from American University. She graduated from the Louisiana State University School of Medicine, where she also did her internship in internal medicine and her residency in neurology.

Prior to practicing medicine, she worked in international relations and owned a foreign language instruction and translation company. 

Brian P. Dunleavy

Author

Brian P. Dunleavy is a writer and editor with more than 25 years of experience covering issues related to health and medicine for both consumer and professional audiences. As a journalist, his work has focused on new research in the treatment of infectious diseases, neurological disorders (including multiple sclerosis and Alzheimer's disease), and pain management. His work has appeared in ADDitude, Consumer Reports, Health, Pain Medicine News, and Clinical Oncology News.

Dunleavy is the former editor of the infectious disease special edition at ContagionLive.com. He is also an experienced sports reporter who has covered the NFL, MLB, NBA, NHL, and professional soccer for a number of publications. He is based in New York City.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Stanak M et al. The Impact of External Trigeminal Nerve Stimulator (e-TNS) on Prevention and Acute Treatment of Episodic and Chronic Migraine: A Systematic Review. Journal of the Neurological Sciences. May 15, 2020.
  2. Now Over-the-Counter: FDA Clears Cefaly Dual Migraine Treatment for Use Without a Prescription. Cision PR Newswire.
  3. Tepper SJ et al. Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial. Headache: The Journal of Head and Face Pain. June 24, 2022.
  4. Non-Invasive Vagus Nerve Stimulation (gammaCore). The Migraine Trust.
  5. Benzion B et al. Is Noninvasive Vagus Nerve Stimulation a Safe and Effective Alternative to Medication for Acute Migraine Control? The Neurologist. July 2020.
  6. Sakharpe AK et al. Occipital Nerve Stimulation. StatPearls. July 3, 2023.
  7. Göbel CH et al. Occipital Nerve Stimulation in Chronic Migraine: The Relationship Between Perceived Sensory Quality, Perceived Sensory Location, and Clinical Efficacy—A Prospective, Observational, Non-Interventional Study. Pain and Therapy. September 10, 2020.
  8. Tepper AJ et al. Real-World Experience With Remote Electrical Neuromodulation in the Acute Treatment of Migraine. Pain Medicine. September 16, 2020.
  9. Nerivio.com.
  10. Single-Pulse Transcranial Magnetic Stimulation (sTMS). The Migraine Trust.
  11. Starling AJ et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. March 4, 2018.